Ocugen's OCU410ST Advances in Clinical Trial for Stargardt Disease, Moving to Medium Dose Testing - MyChesCo
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced a significant advancement in its ongoing clinical trial for Stargardt disease. The Data Safety and Monitoring Board (DSMB) for the …
Timothy Alexander
